A5044627353- Dermatology and Skin Diseases
- Psoriasis: Treatment and Pathogenesis
- T-cell and B-cell Immunology
- Asthma and respiratory diseases
- Allergic Rhinitis and Sensitization
- Immunotherapy and Immune Responses
- Cytokine Signaling Pathways and Interactions
- Urticaria and Related Conditions
- Immune Cell Function and Interaction
- melanin and skin pigmentation
- Autoimmune Bullous Skin Diseases
- Immune cells in cancer
- Immunodeficiency and Autoimmune Disorders
- Mast cells and histamine
- Herpesvirus Infections and Treatments
- Autoimmune and Inflammatory Disorders Research
- Monoclonal and Polyclonal Antibodies Research
- IL-33, ST2, and ILC Pathways
- Spondyloarthritis Studies and Treatments
- Hair Growth and Disorders
- Immune Response and Inflammation
- Cancer Immunotherapy and Biomarkers
- Contact Dermatitis and Allergies
- Cutaneous Melanoma Detection and Management
- Inflammation biomarkers and pathways
Rockefeller University
2011-2020
NYU Langone Health
2019
Probity Medical Research
2005
Background Psoriasis vulgaris is an inflammatory skin disease mediated by Th1 and Th17 cytokines, yet the relative contribution of interferon (IFN)‐γ, interleukin (IL)‐17 IL‐22 on pathogenesis still unknown. Objectives In this study, we sought to identify cytokines produced skin‐resident T cells in normal skin, localize receptors for these examine how alter gene expression profiles bearing cognate receptors. Methods We used intracellular cytokine staining flow cytometry evaluate cell...
Biological agents have dramatically improved treatment options for patients with severe psoriasis. Etanercept (tumor necrosis factor [TNF] receptor-immunoglobulin fusion protein) is an effective many psoriasis patients, and blockade of TNF considered to be its primary action. However, in this clinical trial, we show that etanercept has early inhibitory effects on a newly appreciated type T cells: helper 17 (Th17) cells. reduced the inflammatory dendritic cell products drive Th17...
We find that CD11c(+) cells with many markers of dendritic (DCs) are a major cell type in the skin lesions psoriasis. These cells, which evident both epidermis and dermis, sites for expression two mediators inflammation, inducible nitric oxide synthase (iNOS) TNF-alpha diseased skin. express HLA-DR, CD40, CD86, lack Langerin CD14 Langerhans monocytes, respectively, to significant extent DC maturation DC-LAMP CD83. Treatment psoriasis efalizumab (anti-CD11a, Raptiva) strongly reduces...
The classical Th1/Th2 paradigm previously defining atopic dermatitis (AD) and psoriasis has recently been challenged with the discovery of Th17 T cells that synthesize IL-17 IL-22. Although it is becoming evident many Th1 diseases including have a strong signal, importance in AD still unclear. We examined compared skin biopsies from patients by gene microarray, RT-PCR, immunohistochemistry, immunofluorescence. found reduced genomic expression IL-23, IL-17, IFN-gamma psoriasis. To define...
BackgroundInterleukin 22 promotes epidermal hyperplasia and inhibits skin barrier function.ObjectiveEvaluate interleukin blockade in adults with moderate-to-severe atopic dermatitis (AD).MethodsWe performed a randomized, double-blind, placebo-controlled trial intravenous fezakinumab monotherapy every 2 weeks for 10 weeks, follow-up assessments until 20 weeks. The change SCOring AD (SCORAD) score from baseline at 12 served as the primary end point.ResultsAt mean declines SCORAD entire study...
Psoriasis is a complex disease with an expanding definition of its pathological features. We sought to expand/refine the psoriasis transcriptome using 85 paired lesional and non-lesional samples from cohort patients moderate-to-severe vulgaris who were not receiving active therapy. This new analysis identified 4,175 probe sets (representing 2,725 unique known genes) as being differentially expressed in lesions compared matched biopsies skin when following criteria applied: >2-fold change...
Atopic dermatitis (AD) is the most common inflammatory skin disease, but treatment options for moderate-to-severe disease are limited. Ustekinumab an IL-12/IL-23p40 antagonist that suppresses Th1, Th17 and Th22 activation, commonly used psoriasis patients. We sought to assess efficacy safety of ustekinumab in patients with AD. In this phase II, double-blind, placebo-controlled study, 33 AD were randomly assigned either (n=16) or placebo (n=17), subsequent crossover at 16 weeks, last dose 32...
BackgroundHyperactivity of the IL-23/IL-17 axis is central to plaque psoriasis pathogenesis. Secukinumab, a fully human mAb that selectively inhibits IL-17A, approved for treatment psoriasis, psoriatic arthritis, and ankylosing spondylitis. Secukinumab improves complete spectrum manifestations, with durable clinical responses beyond 5 years treatment. In feed-forward model chronicity, IL-17A has been hypothesized as key driver pathogenic gene expression by lesional keratinocytes, but in vivo...
We used a panel of monoclonal antibodies to characterize DCs in the dermis normal human skin. Staining for CD11c integrin, which is abundant on many kinds DCs, revealed cells upper dermis. These were positive blood DC antigen–1 (BDCA-1; also known as CD1c), HLA-DR, and CD45, markers that are expressed by circulating myeloid DCs. A small subset CD11c+ dermal DEC-205/CD205 DC-lysosomal–associated membrane glycoprotein/CD208 (DC-LAMP/CD208), suggesting some differentiation or maturation. When...
Immunity declines during aging, however the mechanisms involved in this decline are not known. In study, we show that cutaneous delayed type hypersensitivity (DTH) responses to recall antigens significantly decreased older individuals. However, is related CC chemokine receptor 4, lymphocyte-associated antigen, or CD11a expression by CD4+ T cells their physical capacity for migration. Instead, there defective activation of dermal blood vessels subject results from TNF-α secretion macrophages....